Aligos Therapeutics, Inc.

B usiness. Overview We are a clinical-stage biotechnology company focused on developing novel therapeutics to address unmet medical needs in liver diseases and viral infections, including in the areas of chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (e.g., SARS CoV 2, SARS CoV, MERS CoV, and other related infections). The Aligos team has a demonstrated track record of success in drug development and medicinal chemistry in liver and viral diseases, resulting in three potential best in class drug candidates. Our pipeline of drug candidates includes pevifoscorvir sodium (previously known as ALG-000184) for chronic HBV infection, ALG 055009 for MASH and obesity, ALG 097558 for coronavirus infections, and a portfolio of preclinical programs. Pevifoscorvir sodium is our potential best /first in class Capsid Assembly Modulator (CAM E) for chronic HBV infection which has shown in preclinical testing to have enhanced pharmacologic properties vs. competitor CAM E drugs and greater hepatitis B virus deoxyribonucleic acid (HBV DNA) suppression compared to the standard of care, nucleos(t)ide analogs (NAs), and has shown multi-log 10 reductions in viral antigens in a multi part Phase 1 clinical trial spanning up to 96 weeks of treatment. ALG 055009 is our potential best in class thyroid hormone receptor beta (THR ) agonist for MASH and obesity with pharmacologic properties that appear to be enhanced based on data to date vs. competitor THR agonists.